Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

First Trust NYSE Arca Biotechnology Index Fund (FBT)

Delayed Data
As of Nov 20
 -0.75 / -0.61%
Today’s Change
Today|||52-Week Range

Investment Objective

The investment seeks investment results that correspond generally to the price and yield (before the fund's fees and expenses) of an equity index called the NYSE Arca Biotechnology IndexSM. The fund will normally invest at least 90% of its net assets (including investment borrowings) in common stocks that comprise the index. The index is an equal-dollar weighted index designed to measure the performance of a cross section of companies in the biotechnology industry that are primarily involved in the use of biological processes to develop products or provide services. It is non-diversified.

Biotech ETFs: What Lies Ahead?
Nov 13 / Zacks.com - Paid Partner Content


1 month-2.83% 3 years+7.33%
3 months+8.79% 5 years+22.40%
1 year+22.09% Since inception+17.26%
Data through 11/21/2017

Quote Details

Previous close$122.39
Open day’s range121.18 – 122.38
Net asset value (NAV)121.61 (11/20/2017)
Daily volume56,779
Average volume (3 months)55,339
Data as of 3:59pm ET, 11/20/2017

Peer Comparisonvs. Health ETFs

Performance 5-yr return+22.40%+16.79%
Expense Gross exp ratio0.56%1.33%
Risk 5 year sharpe ratio1.031.11
Net assets$1.2B$3.1B
Average market cap$10.8B$27.3B
Average P/E--22.4
Dividend / Share--0.28%


XLV Health Care Select Sector SPDR® Fund
RYH Guggenheim S&P 500® Equal Weight Health...
FHLC Fidelity® MSCI Health Care Index ETF


Top 5 Sectors
Portfolio weighting
Healthcare 100.00%
Business service 0.00%
Consumer goods 0.00%
Consumer service 0.00%
Energy 0.00%
Top 10 Holdings
Portfolio weighting
GRFS Grifols SA3.77%
ALNY Alnylam Pharmaceuticals Inc3.66%
TECH Bio-Techne Corp3.63%
NBIX Neurocrine Biosciences Inc3.62%
IQV Iqvia Holdings Inc3.62%
JUNO Juno Therapeutics Inc3.54%
FGEN FibroGen Inc3.52%
CRL Charles River Laboratories International Inc3.48%
NKTR Nektar Therapeutics3.43%
QGEN Qiagen NV3.42%